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Objective: Despite improved short-term outcomes, concerns remain regarding durability of thoracic endovascular aortic
repair (TEVAR). The purpose of this analysis was to evaluate the pathology-speciﬁc incidence of secondary aortic
interventions (SAI) after TEVAR and their impact on survival.
Methods: Retrospective review was performed of all TEVAR procedures and SAI at one institution from 2004-2011.
Kaplan-Meier analysis was used to estimate survival.
Results:Of 585 patients, 72 (12%) required SAI at a median of 5.6 months (interquartile range, 1.4-14.2) with 22 (3.7%)
requiring multiple SAI. SAI incidence differed signiﬁcantly by pathology (P [ .002) [acute dissection (21.3%), post-
surgical (20.0%), chronic dissection (16.7%), degenerative aneurysm (10.8%), traumatic transection (8.1%), penetrating
ulcer (1.5%), and other etiologies (14.8%)]. Most common indications after dissection were persistent false lumen ﬂow
and proximal/distal extension of disease. For degenerative aneurysms, SAI was performed primarily to treat type I/III
endoleaks. SAI patients had a greater mean number of comorbidities (P < .0005), stents placed (P [ .0002), and
postoperative complications after the index TEVAR (P < .0005) compared with those without SAI. Freedom from SAI at
1 and 5 years (95% conﬁdence interval) was estimated to be 86% (82%-90%) and 68% (57%-76%), respectively. There were
no differences in survival (95% conﬁdence interval) between patients requiring SAI and those who did not [SAI 1-year,
88% (77%-93%); 5-year, 51% (37%-63%); and no SAI 1-year, 82% (79%-85%); 5-year, 67% (62%-71%) (log-rank, P[ .2)].
Conclusions: SAI after TEVAR is not uncommon, particularly in patients with dissection, but does not affect long-term
survival. Aortic pathology is the most important variable impacting survival and dictated need, timing, and mode of SAI.
The varying incidence of SAI by indication underscores the need for diligent surveillance protocols that should be
pathology-speciﬁc. (J Vasc Surg 2014;59:599-607.)After Food and Drug Administration (FDA) approval
in 2005,1 thoracic endovascular aortic repair (TEVAR)
was quickly adopted as the primary treatment strategy for
degenerative thoracic aortic aneurysms.2 Since that time,
this technology has been increasingly utilized to treat
a variety of other pathologies such as traumatic injuries,
penetrating ulcer/intramural hematoma, as well as acute
and chronic dissection.3-7 Despite the early beneﬁts of
TEVAR in reducing morbidity and mortality, long-term
durability is still in question, and uncertainty remains
regarding pathology-speciﬁc incidence of treatment failure.
Because TEVAR has been available for less than
a decade, and there has been a rapid evolution in the appli-
cations of this technology, data regarding the incidence
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://dx.doi.org/10.1016/j.jvs.2013.09.050limited. The purpose of this analysis is to describe the inci-
dence of SAI after TEVAR for various clinical indications
and to determine the effect of secondary interventions on
clinical outcomes, including survival.
METHODS
This study was approved by the Institutional Review
Board at the University of Florida (IRB#528-2011).
Database and patient cohorts. A prospectively main-
tained endovascular aortic registry at the University of Flor-
ida was queried for all patients undergoing TEVAR from
2004 to 2011. All subjects underwent retrospective review
of the electronic medical record and radiographic imaging
to obtain details regarding indications, demographic data,
anatomic, and procedure speciﬁc variables, as well as need
and type of reintervention. Acute and chronic dissection
with aneurysm was deﬁned as previously described by
Hagan et al.8 Speciﬁcally, aortic dissection (AD) treated
<14 days from symptom onset was cataloged as acute
whereas patients treated for dissection $14 days from
symptom onset where characterized as chronic. Comor-
bidities, complications, and adjunctive procedures for
TEVAR were classiﬁed based on the Society for Vascular
Surgery reporting guidelines.9 SAI was deﬁned as any
unplanned open or endovascular procedure required to
treat either the primary pathology (eg, intended treatment
zone) or remote aortic disease (eg, synchronous or meta-
chronous aortic pathology). This speciﬁcally excluded599
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of the TEVAR unrelated to the index aortic pathology (eg,
access vessel repair, iliac artery intervention, or delayed
carotid-subclavian bypass for arm ischemia).
During the study period, 585 patients underwent
TEVAR for various indications, including degenerative
descending thoracic aneurysm (TAA), AD, chronic type
B aortic dissection with aneurysm (CTBAD), postsurgical
anastomotic pseudoaneurysm, traumatic aortic transection
(TAT), penetrating ulcer/intramural hematoma, thora-
coabdominal aneurysm, atheroembolic disease, and Kom-
merel diverticulum. There were 98 (16.7%) patients who
required secondary postoperative procedures, of whom
26 (4.4%) underwent operations for access vessel-related
complications and/or upper-extremity ischemia and were
excluded from the SAI subgroup. The remaining 72
patients (12.3%) received open and/or endovascular SAI
and were compared with patients not undergoing SAI
(n ¼ 513).
Clinical practice. The index TEVAR for the various
aortic pathologies and subsequent SAI were performed at
the discretion of the operating surgeon as were intraopera-
tive adjunctive procedures (eg, access conduit, subclavian
revascularization, and spinal drainage). The following
aortic stent grafts were used during the study interval:
TAG/C-TAG 45% (W. L. Gore and Associates, Flagstaff,
Ariz), Zenith/TX2 40% (Cook Medical Inc, Bloomington,
Ind), Talent/Valiant 9% (Medtronic Inc, Santa Rosa,
Calif), and Bolton Relay 5% (Bolton Medical, Sunrise, Fla).
Previous reports from our group reﬂect a homogeneous
approach to treatment philosophy10 that is based on
a multidisciplinary team of vascular and cardiovascular
surgeons. The practice patterns at the University of Florida
have been previously described in detail regarding
anatomic considerations,11 characteristics of the TEVAR
implantation procedure,11-13 and postoperative care of
patients with TAA,11 AD,13 CTBAD,14 and TAT12 treated
with TEVAR. All patients underwent preoperative
computed tomographic angiography with centerline recon-
struction (TeraRecon, Inc, San Mateo, Calif). Postopera-
tive surveillance consisted of imaging at 1 month,
6 months, and annually thereafter, unless more frequent
imaging was deemed clinically necessary.
Indications and classiﬁcation of SAI. Patients who
underwent SAI (n ¼ 72) were further characterized based
on the initial type of secondary aortic reintervention (endo-
vascular vs open).
Mechanical failure, endograft infection, and ante-
grade/retrograde dissection caused by the TEVAR were
categorized as graft-related complications. Endoleak deﬁni-
tions were based on the SVS reporting guidelines.9 Type
Ia/b and III endoleaks routinely underwent SAI with the
rare exception of patients with prohibitive anatomy and/
or medical comorbidities. Persistent type II endoleak
with continued aneurysm degeneration ($5 mm) beyond
6 months from the index TEVAR also typically underwent
reintervention. For dissections, the most common rationale
for SAI was a persistent patent false lumen resulting incompromised proximal/distal ﬁxation, visceral/lower
extremity malperfusion, persistent pain, or continued false
lumen aneurysmal degeneration. Finally, common indica-
tions for SAI in TAA patients included remote aortic
degeneration (eg, aortic site not in immediate apposition
to the endograft or intended treatment zone) or synchro-
nous multilevel aortic disease.
Study end points and statistical analysis. The
primary end point was the rate of SAI following the index
TEVAR. Additional end points included complications
following SAI and mortality. All deaths were veriﬁed by
query of the Social Security Death Masterﬁle.
Statistical analyses were completed using STATA 11
(StataCorp, College Station, Tex) and the R statistical soft-
ware package (www.r-project.org; V.2.15.0). Categorical
variables were summarized using frequencies and percent-
ages, whereas continuous variables were evaluated with
mean and standard deviation (6 SD) if normally distrib-
uted and median values with interquartile range (IQR), if
not. Comparisons of patient or procedure-related charac-
teristics in subgroup analyses were performed using the
Fisher exact test, two-sample t-test, or Wilcoxon rank
sum test as appropriate. Patient survival and SAI rates
were estimated using Kaplan-Meier methodology and
compared between groups using the log-rank test. Statis-
tical signiﬁcance was assumed at a P value of <.05.RESULTS
Over the study period, 585 patients (mean age 6 SD,
65.36 15.2; 32% female, n ¼ 185) underwent TEVAR for
treatment of 384 (66%) elective and 201(34%) urgent or
emergent thoracic aortic pathologies. The most common
indication was degenerative descending thoracic aortic
aneurysm, which accounted for 46% of all procedures
(Fig 1, A). Dissection-related pathology was the index
TEVAR indication in 27% of cases, which constituted the
second largest subgroup. ‘Other’ indications (5%) included
mycotic etiologies, atheroembolic disease, thoracoabdomi-
nal aneurysms, and Kommerel diverticulum.
The rate of SAI by index TEVAR indication is depicted
in Fig 1,B. Patients with AD, postsurgical anastomotic pseu-
doaneurysm, and CTBAD had the highest overall rates of
SAI. Patients with dissection-related pathologies had nearly
double the SAI rate of those undergoing TEVAR for degen-
erative aneurysm (P ¼ .02). Focal pathology such as TAT
(8.1%) and penetrating ulcer/intramural hematoma (1.5%)
had the lowest rates of SAI. The demographics and comor-
bidity proﬁle of patients requiring SAI compared with those
who did not are depicted in Table I. Notably, patients
requiring SAI were more likely to be male and had signiﬁ-
cantly greater prevalence of multiple comorbidities
compared with patients who did not (P ¼ .04).
Indications for SAI after TEVAR
Fig 2 provides speciﬁc details regarding the
SAIs performed after TEVAR for patients with AD,
CTBAD, and TAA; the three most common index TEVAR
Table I. Demographics and comorbidities of patients:
no secondary aortic intervention (SAI) vs SAI
Feature
No SAI
(n ¼ 513)
þ SAI
(n ¼ 72) Pa
Age, years 65.7 6 15.1 63.1 6 16.0 .1
Sex (female) 172 (34) 13 (18) .01
Body mass index 27.4 6 5.7 28.1 6 5.0 .3
Hypertension 143 (28) 40 (56) <.0005
Dyslipidemia 64 (12) 21 (29) .001
Coronary artery disease 38 (7) 12 (17) .02
COPD 38 (7) 11 (15) .04
Congestive heart failure 12 (2) 3 (4) .4
Renal insufﬁciency
(Cr $ 1.8)
45 (9) 8 (11) .5
Composite 0.7 6 1.3 1.4 6 1.5 <.0005
COPD, Chronic obstructive pulmonary disease; Cr, creatinine; SD, standard
deviation.
Continuous data are presented as mean ± SD and categorical data as
number (%).
at-test for continuous variables or c2 or Fisher exact test for categorical
variables when appropriate.
Fig 1. A, Indications for the initial thoracic endovascular aortic repair (TEVAR) by aortic pathology. Notably, 73% of
the index TEVARs was performed for dissections and degenerative aneurysms. B, Incidence or rate of secondary aortic
intervention (SAI) during follow-up stratiﬁed by initial TEVAR indication. CTBAD, Chronic type B aortic dissection
with aneurysm; TAA, thoracic aneurysm.
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(n ¼ 59) of the cases requiring SAI.
Acute dissection. For AD patients (n ¼ 75) treated
with TEVAR, 21.3% (n ¼ 16) required SAI. Median
time to SAI after TEVAR for AD was 1 month (IQR,
0.4-1.8). Of the 16 patients in the AD SAI cohort,
a majority (69%; n ¼ 11) had an open operation as their
initial remedial procedure and 31% (n ¼ 5) underwent
multiple SAI (Fig 2, A). Initial SAI was urgent or emer-
gent in 14 of 16 patients (87.5%). Types of open SAI after
TEVAR for AD included ascending/transverse arch
reconstruction (n ¼ 4) and proximal/distal cerclage
utilizing a Dacron graft (n ¼ 6). One patient underwent
surgical conversion with device explantation because of
false lumen rupture on postoperative day one. The most
prevalent indications for the various open surgical revisionswere a persistent patent false lumen resulting in continued
pain (n ¼ 2), false lumen expansion (n ¼ 2), retrograde
dissection (n ¼ 3), and hemothorax/rupture (n ¼ 4).
Similarly, a persistent patent false lumen with intrac-
table pain (n ¼ 1) or communication with a false lumen
rupture (n ¼ 4) led to endovascular SAI utilizing prox-
imal/distal endograft extension and/or embolization in
another ﬁve patients.
Chronic dissection with aneurysm. For patients with
CTBAD, 17% (n ¼ 14) underwent SAI at a median time of
7 months (IQR, 3.7-13.3) after TEVAR. Of these, initial
open and endovascular SAI were evenly distributed with
28.5% (n ¼ 4) requiring multiple SAI. Ascending/trans-
verse arch reconstruction was required in one patient due
to a proximal endoleak resulting in a persistent patent false
lumen and continued aneurysm expansion whereas
a second patient experienced retrograde dissection 1.5
months after the initial TEVAR. Cerclage of the thoracic
aorta around the endograft with intercostal artery ligation
was successful in two additional patients who had a persis-
tent patent false lumen. Late open conversion was required
in three cases due to proximal (Gore TAG; W. L. Gore and
Associates) endograft collapse (1), distal (Gore TAG)
endograft in-folding (1), and distal thoracic/visceral
aortic degeneration (1) (Fig 2, B).
For patients who had initial endovascular SAI (n ¼ 7)
after TEVAR for CTBAD, the most common indication
was a persistent patent false lumen from proximal (n ¼
2) or distal/remote site septal fenestrations (n ¼ 5). Rein-
tervention strategies included proximal endograft exten-
sion in two patients whereas two others underwent distal
extension to the level of the celiac artery. Two additional
subjects underwent stent graft placement across a large
visceral septal fenestration for a persistent patent false
lumen. A single patient underwent embolization of the
left subclavian artery due to retrograde ﬁlling of the false
lumen (Fig 2, B).
Fig 2. Flowchart of secondary aortic interventions (SAI) stratiﬁed by the three most common thoracic endovascular
aortic repair (TEVAR) indications. A, Acute aortic dissection (AD). B, Chronic type B aortic dissection with aneurysm
(CTBAD) and aneurysm. C, Thoracic aneurysm (TAA). endo, Endovascular.
Table II. Operative details of the index thoracic
endovascular aortic repair (TEVAR)
Feature
No SAI
(n ¼ 513)
þ SAI
(n ¼ 72)
P
valuea
Prior AAA repair 97 (19) 10 (14) .3
Procedure details
Urgent/emergent 169 (33) 32 (44) .06
ASA III/IV 398 (78) 56 (78) 1
Number stents 2.1 6 1.0 2.6 6 1.3 .0002
Left subclavian coverage 255 (50) 38 (53) .7
Adjunct 174 (34) 30 (42) .2
Complication with ﬁrst
TEVAR
165 (32) 46 (64) <.0005
Length of stay, days 8 6 10 13 6 19 .005
AAA, Abdominal aortic aneurysm; ASA, American Society of Anes-
thesiologists; SD, standard deviation.
Continuous data are presented as mean ± SD and categorical data as
number (%).
at-test for continuous variables or c2 or Fisher exact test for categorical
variables when appropriate.
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related pathology, the majority (76%; n ¼ 22) of initial
SAI for TAA were endovascular procedures. However,
similar to acute and chronic dissection patients, approxi-
mately one-third of the SAI patients (34%; n ¼ 9) required
multiple SAI (Fig 2, C). Median time to SAI was signiﬁ-
cantly longer at 13.1 months (IQR, 4.7-14.9; P < .0005)
for TAA compared with dissection-related pathology.
Notably, of the 22 patients undergoing endovascular SAI,
20 (91%) underwent proximal or distal extension for type I
endoleak or a bridging stent placement for type III endo-
leak. Of the minority of patients requiring open SAI, two
underwent transverse arch replacement and two underwent
open repair with either endograft removal (one) or incor-
poration of the prior endograft into the repair (one).
Type and outcome of SAI after TEVAR
Operative details of the index TEVAR for patients
requiring SAI vs those who did not are highlighted in
Table II. The mean number of stents deployed, incidence
of postoperative complications, and overall length of stay
with the index TEVAR were all signiﬁcantly greater in
patients who subsequently required SAI. No association
between device type used during the index TEVAR and
subsequent SAI was noted (P ¼ .1). The types of SAI
and indications (n ¼ 112 procedures in 72 patients) are
outlined in Table III. Multiple SAIs were required in
31% (n ¼ 22) of patients, and notably there were 4 arch
reconstructions performed for retrograde AD. The patients
who developed retrograde AD after TEVAR were initially
treated with a Gore TAG device (W. L. Gore and Associ-
ates) (n ¼ 2) and a Cook Zenith TX2-Proform device
(Cook Medical Inc) (n ¼ 2).
Outcomes following the initial SAI, based on whether
this was an endovascular or open procedure, are reported in
Tables IV and V, respectively. Speciﬁcally, for patients thatunderwent SAI after TEVAR, outcomes were examined
with respect to the initial SAI (as several patients required
multiple open or endovascular SAI). Length of stay, 30-
day mortality, and postoperative complications following
open SAI were comparable to reported rates after open
thoracic aortic surgery.5,15-17 Similarly, clinical outcomes
following endovascular SAI were not worse than that after
the index TEVAR.
Incidence and survival impact of SAI after TEVAR
At a median follow-up of 5.8 months (IQR, 0.9-25.8),
the 1- and 5-year freedom from SAI after TEVAR for the
entire cohort were estimated to be 86% (95% conﬁdence
interval [CI], 82%-90%) and 68% (57%-76%), respectively
(Fig 3). Stratiﬁcation by pathologic indication for TEVAR
Table III. Indications and descriptions of secondary aortic intervention (SAI) (n ¼ 112) in all thoracic endovascular
aortic repair (TEVAR) patients (n ¼ 72)
Rationale for reintervention No. (%) (n ¼ 112)
Type of SAI procedure
Open repair (n ¼ 46) Endovascular (n ¼ 65)
Endoleak
Type 1a 15 (13.4) Arch reconstruction 1 Proximal extension 11
Cerclage 1
Surgical conversion 2
Type 1b 7 (6.3) Cerclage 1 Distal extension 5
Type IV TAAA 1
Type II 14 (12.5) Embolization 11
Proximal extension 2
Relining 1
Type III 4 (3.6) Bridge graft 4
Type IV 2 (1.8) Relining 2
Persistent false lumen ﬂow
Proximal ﬁxation 7 (6.2) Arch reconstruction 4 Proximal extension 2
Surgical conversion 1
Distal ﬁxation 14 (12.5) Cerclage 5 Distal extension 7
Surgical conversion 2
Proximal and distal ﬁxation 2 (1.8) Cerclage 2
Remote site fenestration 8 (7.1) Surgical conversion 1 Visceral/renal stent graft 3
Distal extension 2
Chimney EVAR 1
Left subclavian embolization 1
Graft complicationa 14 (12.5) Surgical conversion 5 Proximal extension 4
Arch reconstruction 1 Distal extension 1
Cerclage 1 Proximal þ distal extension 1
Retrograde dissection 4 (3.6) Arch replacement 4
Disease progression and/or remote aortic
procedure
20 (17.9) Visceral and/or infrarenal 10 Hybrid repair 3
Ascending arch replacement 1 Infrarenal aortic stent graft 3
Proximal thoracic extension 1
Chimney EVAR 1
Fenestrated EVAR 1
Aortobronchial ﬁstula 1 (<1) Partial graft excision 1
Aortoesophageal ﬁstula 1 (<1) Graft removal 1
EVAR, Endovascular aneurysm repair; TAAA, thoracoabdominal aneurysm.
aGraft complication includes arch pseudoaneurysm post-TEVAR, enfolding, retraction, infection, and acute precipitation of false lumen rupture; Hybrid
repair ¼ visceral aortic debranching with endovascular aortic stent graft (EVAR).
Table IV. Outcomes after open secondary aortic
intervention (SAI) for thoracic endovascular aortic repair
(TEVAR)
Feature Open (n ¼ 30)
Length of stay, days, mean 6 SD 20 6 16
30-day mortality 7%
Complication 53%
Neurologic 23%
Spinal cord ischemia 17%
Stroke 7%
Pulmonary 33%
Cardiac 3%
Bleeding/wound 13%
Renal (25%YeGFR) 17%
eGFR, Estimated glomerular ﬁltration rate; SD, standard deviation.
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between TAA, CTBAD with aneurysm, and AD (P <
.0005).
Survival in the entire TEVAR cohort at 1 and 5 years
was estimated to be 83% (95% CI, 80%-86%) and 64%(95% CI, 60%-69%), respectively. No signiﬁcant difference
in mortality was found between patients requiring SAI and
those who did not (P ¼ .2; Fig 5). Furthermore, within
each major pathologic indication for TEVAR (AD,
CTBAD, and TAA), SAI did not inﬂuence patient survival.
In addition, neither the mode of the initial SAI, whether
open or endovascular, nor if the patient ever underwent
open SAI, had an impact on long-term survival (P ¼ .9
and P ¼ .1, respectively). However, survival was signiﬁ-
cantly different when patients were stratiﬁed by aortic
pathology (P ¼ .03; Fig 6).
DISCUSSION
This study is consistent with the existing literature and
demonstrates that SAI after TEVAR is common, and these
results emphasize the importance of long-term surveillance
after thoracic endovascular procedures for any indication.
For the three most common indications for TEVAR
(AD, CTBAD with aneurysm, and TAA), signiﬁcant differ-
ences in the timing and mode of reintervention were noted,
with the highest rate of SAI found in dissection patients.
Table V. Outcomes after endovascular secondary aortic
intervention (SAI) for thoracic endovascular aortic repair
(TEVAR)
Feature
Endo SAI
(n ¼ 42)
Index TEVAR
(n ¼ 585)
P
valuea
Length of stay, days, mean 6 SD 6 6 7 9 6 12 .14
30-day mortality 0% 6% .2
Complication 14% 36% .004
Neurologic 5% 15% .06
Spinal cord ischemia 2% 9% .1
Stroke 0% 8% .06
Pulmonary 2% 8% .2
Cardiac 7% 4% .3
Bleeding/wound 2% 5% .4
Renal (25%YeGFR) 5% 6% .8
Endo, Endovascular; eGFR, estimated glomerular ﬁltration rate; SD, stan-
dard deviation.
at-tests for continuous variables or c2or Fisher exact tests for categorical
variables when appropriate.
Fig 3. Freedom from secondary aortic intervention (SAI) after the
index thoracic endovascular aortic repair (TEVAR). One- and 5-
year freedom from SAI (with 95% conﬁdence interval [CI]) were
estimated at 86% (82%-90%) and 68% (57%-76%), respectively, for
the entire cohort of patients (n ¼ 585).
Fig 4. Freedom from secondary aortic intervention (SAI) when
stratiﬁed for the three most common indications for the index
thoracic endovascular aortic repair (TEVAR). Rate of SAI was
highest for the acute dissection, followed by chronic dissection
with aneurysm and then degenerative aneurysms. CTBAD,
Chronic type B aortic dissection with aneurysm; TAA, thoracic
aneurysm.
Fig 5. Survival impact of secondary aortic intervention (SAI)
following thoracic endovascular aortic repair (TEVAR). No
difference in survival was noted between patients who underwent
SAI and those who did not.
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of aortic coverage, such as penetrating ulcers or traumatic
transections, had relatively low rates of SAI. Both the
mode of SAI as well as the time to the ﬁrst SAI was strongly
associated with aortic pathology. Despite the frequent need
for repeat intervention after the index TEVAR, neither the
need for SAI nor the mode of reintervention impacted
long-term survival, which was primarily dictated by the
pathologic indication for the index TEVAR.
TEVAR has been increasingly utilized for a number of
acute and chronic aortic conditions due to reduced
morbidity and mortality when compared with open
repair.4,18-22 Although there is a lower risk of perioperative
morbidity and mortality after endovascular therapy, life-
long monitoring is required due to the ongoing risk of
treatment failure. Reintervention after TEVAR is notuncommon and has previously been reported to be as
high as 38%-72% at 3 years19,23,24 for AD patients, 13%-
41% for CTBAD patients,25,26 and 8%-22% for TAA
patients,27,28 which are all comparable to results found in
this series. Notably, no speciﬁc devices were found to be
associated with an increased risk of SAI in this series, which
is also consistent with other reports.27,28
In many cases, treatment of dissection with TEVAR
violates the basic premise of endovascular repair because
of the inherent lack of seal when the device lands in the
dissected aorta. Therefore, the lack of durability in the
dissection patients is not particularly surprising given the
fragile nature of the tissues involved in the repair, especially
Fig 6. Survival when stratiﬁed for the three most common indi-
cations for the index thoracic endovascular aortic repair (TEVAR).
Survival was lowest following TEVAR for acute dissection, fol-
lowed by degenerative aneurysms, and then chronic dissection
with aneurysm. CTBAD, Chronic type B aortic dissection with
aneurysm; TAA, thoracic aneurysm.
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1 month, 21% of AD patients underwent a remedial proce-
dure, with a majority of these (69%) undergoing an open
intervention. The most frequent indications were rupture
and malperfusion from a persistent patent false lumen.
Notably, six patients underwent aortic banding/cerclage
around the endograft, however, this strategy has since
been abandoned due to a high rate of failure and at the
present time, we perform direct aortic reconstruction
when TEVAR failure occurs in the management of AD.
SAI occurred in 17% of our CTBAD patients, which
was similar to that of AD patients. However, the interven-
tions occurred later, at a median of 7 months, and were
equally distributed between open and endovascular inter-
ventions, unlike AD patients who were more often repaired
with an open approach. The rate of SAI for CTBAD
patients in our series is comparable to the 22% reported
by Kang et al,26 as was the time to reintervention, which
was a median time of 10.1 months in their study. Similarly,
approximately one-half of the procedures were distal to the
initial TEVAR and performed to treat a persistent patent
false lumen and aneurysm expansion analogous to the
43% of SAI performed to address distal false lumen aneu-
rysm formation in patients with CTBAD in other
reports.26,30 Further, Sayer and colleagues24 reported 3-
year freedom from SAI in CTBAD patients as 45%, which
is comparable to the 63% in our series. These reported rates
of reintervention after TEVAR for dissection demonstrates
that SAI may eventually become an expected part of the
treatment paradigm for these patients.
Our series demonstrates that degenerative pathology
has a lower incidence of SAI and a higher probability of
successful remediation with endovascular techniques
compared with dissection. Similar to other series,27,28 the
most common indication for reintervention after TEVARfor TAA was type 1 endoleak requiring endograft extension
(Table III). The overall occurrence of reintervention after
TEVAR for TAA was 10.8% and the vast majority (76%)
underwent endovascular intervention. The open surgical
conversion rate in our series (1.1%) is similar to other
reports where conversion rates approach 2%-6%.27,28
Notwithstanding the ﬁnding that SAI patients gener-
ally had a higher number of comorbidities compared with
the non-SAI cohort, the postoperative complications
following endovascular (14%) and open SAI (53%) after
TEVAR were similar to those following primary endovas-
cular and open surgical repair of a variety of thoracic and
thoracoabdominal disease indications.5,27,31-33 Interest-
ingly, despite the risk of additional morbidity and mortality
after undergoing SAI, there was no difference in survival
between patients who required aortic remediation after
TEVAR and those who did not. Furthermore, there was
also no difference in survival based on the initial mode of
SAI required, whether open or endovascular, or whether
the patient ever underwent open SAI. The primary factors
determining survival following TEVAR in this study were
aortic pathology and patient comorbidities. The signiﬁ-
cance of these two factors is demonstrated in Fig 5 where
patients treated for CTBAD had the best survival, followed
by TAA and then AD patients who had the worst. This
mortality trend by pathology is consistent with data from
Patterson et al, who reported on the midterm outcomes
from the Medtronic Thoracic Endovascular Registry.34
Although CTBAD patients more frequently required SAI
compared with TAA patients, these patients had fewer
risk factors previously reported by our group to be inde-
pendent predictors of mortality compared with their TAA
counterparts (1.8 6 0.8 vs 2.2 6 0.9; P ¼ .002).10
The differential rate of SAI by pathology demonstrates
that it may be inappropriate to have a standard surveillance
protocol that includes all indications. Although this study
was not designed to determine the optimal surveillance
imaging protocol for a variety of thoracic aortic patholo-
gies, the relatively high rate and early occurrence of SAI
in AD patients suggests that the optimal timing of the ﬁrst
postoperative computed tomography might be earlier than
that for focal pathologies, and more frequent imaging may
be warranted in the early postoperative period. Further-
more, given the rate of multiple SAIs among dissection
and TAA patients (w30%), patients requiring a secondary
aortic procedure may beneﬁt from increased imaging
frequency.
The limitations of this study include its retrospective
nature and the relatively small patient numbers within
each index TEVAR indication cohort. Although multiple
comorbidities and certain pathologies were identiﬁed to
be associated with SAI, no predictive modeling for SAI
was possible given the small patient numbers within each
SAI cohort, which prevented robust statistical modeling.
Additionally, no standardized prospective algorithm was
in place to control for patient selection, device implanta-
tion, or rationale for reintervention. The inﬂuence of selec-
tion bias on timing and need for reintervention, particularly
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study.
An important consideration in this analysis is that less
than 25% of these cases were performed within the
constraints of a clinical trial and, therefore, endografts
initially designed, tested, and approved for chronic aneu-
rysmal pathology were implanted ‘off-label.’ These results
underscore the current limitations of stent graft design,
particularly for acute and chronic dissection. The endograft
frequently must adapt to signiﬁcant differences in lumen
diameter between the proximal and compressed distal
true lumen and the next generation of stent graft design
will likely have pathology-speciﬁc device modiﬁcations to
address these challenges (eg, PETTICOAT35 [provisional
extension to induce complete attachment] technique now
being evaluated for acute dissection). Finally, given that
the index TEVAR was performed at a tertiary referral
center, there is the possibility of missed SAIs performed
at other institutions that may inﬂuence the ﬁndings.
CONCLUSIONS
SAI after TEVAR is common, particularly in patients
treated for dissection-related pathology but does not
appear to negatively affect long-term survival. Aortic
pathology was the most important variable impacting
survival as well as dictating the need, timing and mode of
SAI. The prevalence of these secondary procedures under-
scores the need for diligent surveillance protocols that
perhaps should be pathology-speciﬁc.
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